This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Global cell and gene therapy development and manufacturing business expands into Bruntwood SciTech’s Alderley Park to boost manufacturing capacity.The 17,000 sq ft high-specification lab space is currently under construction, expanding plasmid DNA and viral vector capabilities in Europe.The facility will support therapeutic developers with rapid access to High Quality plasmid, with manufacturing slots available from summer 2022.
Finding small molecule drugs is much harder than finding a needle in a haystack – discovering the right arrangement of atoms to bind precisely to a protein target to elicit a particular response is a problem of vast dimensionality. We are most familiar with the numbers involved when dealing with antibodies: a typical antibody library might contain 10 13 different clones – but even that hardly scratches the surface of the 10 80 or so possible CDR sequences.
Today’s guest post comes from John Beardsley, Senior Vice President of Corporate Strategy at CoverMyMeds. John discusses some of the findings in CoverMyMeds’ recently published report on medication access. He describes patient-centric, data-driven solutions to help patients access, afford, and adhere to their therapies. To learn more, download CoverMyMeds’ 2022 Medication Access Report.
This chart shows the pharmaceutical companies with the most patents in Cyprus. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Cyprus? appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
A lot has changed over the past few decades in the way clinical trials are conducted. Advances in data management systems, risk-based monitoring, pharmacovigilance, electronic databases, and application of complex […]. The post Clinical Trial Outsourcing and Management in USA appeared first on ProRelix Research.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
In this post, we explore why and how to use in vitro screening to identify biomarkers. A case study is also provided to highlight exactly how in vitro screening can be used to develop a biomarker signature of drug response.
Today’s guest post comes from Jeff Berkowitz, CEO of advisory firm Real Endpoints. Jeff describes problems with Medicare copays that reduce adherence and persistence among seniors. He then describes RE Assist , Real Endpoints’ tech-enabled solution with key information on foundations for more than 30 diseases. To learn more about Medicare copayments and how the RE Assist solution helps patients, register to view Real Endpoints’ free webcast: Solving the Medicare Co-pay Dilemma.
This chart shows the drugs with the most patents in Germany. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Germany? appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The World Health Organization (WHO) defines clinical trials as a type of research that studies new tests and treatments and evaluates their effects on human health outcomes (1). Clinical trials […]. The post Clinical Trial Approval Process in Australia appeared first on ProRelix Research.
Olivia Price It has been one year since the COVID-19 vaccine rollout commenced in Australia, and while vaccination rates initially lagged behind other countries, over 95% of Australians aged 12 years and older are now fully vaccinated. We tend to consider the remaining unvaccinated people a homogenous ‘anti-vax’ group. However, there are some less vocal, disadvantaged populations with lower rates of vaccine uptake who require targeted efforts to increase uptake.
• Face-to-face event, taking place in London, UK, 26-27th April, will feature two dedicated tracks: ‘Scientific’, focused on seven core therapy areas and ‘Life Sciences Business’ Programme features keynote from George Freeman MP, with an update on the UK Government Life Sciences VisionRegistration for BioTrinity 2022 now available online
At the American Chemical Society Spring National Meeting & Expo, Atomwise members were selected to present their research and work. Learn what our Atoms have been working on below and visit Atomwise at ACS Spring 2022 National Meeting for other presentation sessions.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Today’s guest post comes from Garry Marshall, Senior Director of Business Strategy at Wolters Kluwer, Health. Garry discusses healthcare business vertical integration and its effect on care quality for patients and on providers' work experiences. To learn more, download the Wolters Kluwer Expert Insight article Vertical Integration Strategies: Using Data to Align Partners and Reduce Variation in Care.
This chart shows the pharmaceutical companies with the most patents in Slovakia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Slovakia? appeared first on DrugPatentWatch - Make Better Decisions.
Allergan, an AbbVie (NYSE: ABBV) company, today announced new data to be presented from Allergan’s leading portfolio of eye care treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting being held in Nashville, TN and virtually from March 3-6. Presentations will include updated analyses that help further scientific understanding of DURYSTA ® (bimatoprost intracameral implant), as well as new data on the XEN ® Gel Stent.
The recent SLAS 2022 conference showcased some great presentations and panel discussions on the transformative potential of laboratory automation and AI-driven machine learning. Strateos’ SVP of Strategy & Operations, Daniel Sipes, echoed this sentiment during his presentation on how automated labs are accelerating medicinal chemistry (MedChem) cycles for drug discovery.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
At the American Chemical Society Spring National Meeting & Expo, Atomwise members were selected to present their research and work. Learn what our Atoms have been working on below and visit Atomwise at ACS Spring 2022 National Meeting for other presentation sessions.
The boffins at the Centers for Medicare & Medicaid Services (CMS) recently dropped the latest National Health Expenditure (NHE) data, which measures all U.S. spending on healthcare. (See links below.) These data provide our first official look at how the pandemic has affected U.S. healthcare spending. Today, I examine the key insights from these latest figures.
This chart shows the pharmaceutical companies with the most patents in Cyprus. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Cyprus? appeared first on DrugPatentWatch - Make Better Decisions.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Designation is supported by Phase II efficacy and safety data that will be presented at ATS 2022 Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases. Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its novel investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis (IPF).
Prurigo nodularis (PN) is a rare skin disorder that causes hard, itchy, or painful bumps to appear on the skin. Symptoms of PN usually begin to appear in middle-aged adults, but it can affect people of all ages. What Does Prurigo Nodularis Look Like? The primary symptom of prurigo nodularis is the appearance of firm, itchy or painful lumps called nodules on the skin.
Strateos is pleased to be taking part alongside other thought leaders in the field of lab automation at PharmaIQ Live: SmartLab Digital 2022 on March 8-9, 2022. John Harman, Strateos’ Senior Director of Product Management will be presenting a talk focused on accelerating drug discovery workflows through automation, robotics, and lab digitalization.
Today’s guest post comes from Jason Zemcik, Vice President of Patient Affordability at TrialCard. Jason discusses two approaches to address the CMS Final Rule on manufacturer coupons and Best Price: the pharmacy copay offer and direct reimbursement to the patient. He goes on to describe TrialCard’s reimbursement capability solutions. To learn more about TrialCard Pay and how to prepare your copay program for the future, register for Solving the Best Price and Co-Pay Challenge – A Framework for A
This chart shows the drugs with the most patents in Finland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Finland? appeared first on DrugPatentWatch - Make Better Decisions.
A vaccine manufactured in plants and developed in Canada. Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID?
Discover how high-content screening (HCS) can be used with 3D in vitro models to drive the discovery and development of novel oncology and immuno-oncology therapeutics.
52
52
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content